Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucose Consumption in MS Utilizing [F-18]FDG-PET
NCT07087106Phase 4
Key facts
- Status
- Recruiting
- Start
- May 2025
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Brigham and Women's Hospital
- Modality
- Small Molecules
- Drugs
- fludeoxyglucose f 18
- Conditions
- multiple sclerosis (MS)
01
Overview
Phase 4, open-label, single-arm trial of fludeoxyglucose f 18 in multiple sclerosis (MS), sponsored by Brigham and Women's Hospital. Primary endpoint: Glucose consumption measured by [F-18]FDG-PET. Started May 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
PMS, RRMS, and Healthy Control subjects
Subjects with progressive MS, relapsing-remitting MS, and healthy controls receiving [F-18]FDG for PET imaging.
03
Who it enrols
Adults aged 18-70 with progressive or relapsing-remitting MS, or healthy controls, willing to undergo PET and MRI imaging. Excludes pregnant women, individuals with alternate neurologic/neuropsychiatric disorders, claustrophobia, non-MRI compatible devices, or recent corticosteroid use.
04
Endpoints
Primary
Glucose consumption measured by [F-18]FDG-PET
Secondary
Correlations between PET measurements and clinical, MRI, and blood/serum measures
Beyond the preview
Go deeper on NCT07087106.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087106.